Informations générales (source: ClinicalTrials.gov)
Prognostic and Predictive Biomarkers in Ovarian Cancers
Interventional
N/A
Gustave Roussy, Cancer Campus, Grand Paris (Voir sur ClinicalTrials)
septembre 2016
septembre 2032
28 août 2025
The investigators therefore propose to conduct a biological study of prospectively
collected patient tumour samples, ascites, blood and other residual samples (feces,
urine, vaginal smear) throughout the disease course where markers (at diagnosis and their
change with treatment) will be correlated to outcome in order to investigate how genetic
diversity in OC prior to treatment and adaptation following treatment contribute to
chemotherapy resistance. In addition freshly collected ascitic samples (and tumour
samples) will be subjected to ex vivo DNA repair functional assays and isolated in
primary culture (and established as xenografts) for target validation experiments.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | Alexandra LEARY | 29/05/2024 12:42:40 | Contacter | ||
Critères
Femme
Inclusion Criteria:
1. New patient with a diagnosis of OC, or
2. Previously treated patient with frozen or formalin fixed paraffin embedded primary
tumour sample available that can be retrieved by the center presenting with
progressive disease, and consenting to CT guided biopsy of relapsed disease, or
3. Previously treated patient with frozen or formalin fixed paraffin embedded primary
tumour sample available that can be retrieved by the center scheduled for surgery
for relapsed disease.
4. Signed informed consent
5. Age ≥ 18
6. Patient affiliated to a social security regimen or beneficiary of the same
1. New patient with a diagnosis of OC, or
2. Previously treated patient with frozen or formalin fixed paraffin embedded primary
tumour sample available that can be retrieved by the center presenting with
progressive disease, and consenting to CT guided biopsy of relapsed disease, or
3. Previously treated patient with frozen or formalin fixed paraffin embedded primary
tumour sample available that can be retrieved by the center scheduled for surgery
for relapsed disease.
4. Signed informed consent
5. Age ≥ 18
6. Patient affiliated to a social security regimen or beneficiary of the same
1. Patients who do not fit the inclusion criteria and those who refuse an antitumoral
treatment;
2. Coagulation abnormalities that contra-indicates the biopsy